Background: Caspofungin has shown efficacy in empirical antifungal therapy in neutropenic
patients, refractory invasive Aspergillus infections and invasive candidiasis. Here we report …

Objectives Caspofungin is used for treatment of invasive fungal infections. As the
pharmacokinetics (PK) of antimicrobial agents in critically ill patients can be highly variable …

Background. The standard caspofungin treatment regimen (50 mg/day after a 70-mg dose
on day 1) is effective and well tolerated for the treatment of invasive candidiasis, but …

BACKGROUND Neutropenia is an indicator of poor prognosis in patients with fungal
infections. All available clinical trial experience from the caspofungin development program …

Invasive fungal infections are important causes of morbidity and mortality in hospitalised
patients. Current therapy with amphotericin B and antifungal triazoles has overlapping …

Caspofungin is an echinocandin with proven efficacy in invasive candidiasis (IC) and
invasive aspergillosis (IA). This multicenter, prospective, non-comparative, observational …

OBJECTIVES: Combination of caspofungin and another anti-fungal agent raise expectation
of improved efficacy in severe fungal infections including failures to first line therapy …

Objectives Caspofungin has demonstrated efficacy in invasive candidiasis. However, in a
comparative study, most patients (> 83%) had candidaemia. Therefore, we performed a …

Objectives: Although a paediatric dosage has not been established, caspofungin is
occasionally used in paediatric patients. We conducted a multicentre retrospective survey to …

Introduction Candidemia is the fourth frequent reason of healthcare-related bloodstream
infections in critically ill patients. For initial management of (suspected) invasive candidiasis …